DFO
PTGX icon

Duquesne Family Office’s Protagonist Therapeutics PTGX Stock Holding History

Duquesne Family Office’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6M Buy
208,900
+49,200
+31% +$5.14M 0.49% 42
2026
Q1 		$16.8M Hold
159,700
– – 0.5% 44
2025
Q4 		$13.9M Hold
159,700
– – 0.31% 49
2025
Q3 		$10.6M Buy
+159,700
New +$9.08M 0.26% 57

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Duquesne Family Office's PTGX Position: Q2 2026 in Review

Duquesne Family Office increased its Protagonist Therapeutics (PTGX) stake by 31% in Q2 2026, buying an estimated $5.14M and bringing the position to 208,900 shares worth $25.6M. The position accounts for 0.49% of the portfolio, ranked #42.

Duquesne Family Office first reported a position in PTGX in Q3 2025 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Duquesne Family Office held 208,900 shares of Protagonist Therapeutics worth $25.6M as of Q2 2026.
  • Duquesne Family Office bought 49,200 Protagonist Therapeutics shares in Q2 2026, an estimated $5.14M.
  • Protagonist Therapeutics made up 0.49% of Duquesne Family Office's portfolio in Q2 2026, its #42 holding.
  • Duquesne Family Office first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.